SOURCE: StockCall


November 22, 2010 08:41 ET

Opinions on Bristol-Myers Squibb and Merck & Co. Inc. - Big Pharma Under Increased Regulatory Scrutiny

JOHANNESBURG, SOUTH AFRICA--(Marketwire - November 22, 2010) - offers investors comprehensive research on the drug manufacturers - major industry and has completed analytical research on Bristol-Myers Squibb Co. (NYSE: BMY) and Merck & Co. Inc. (NYSE: MRK). Register with us today at to have free access to these researches. 

Last month's settlement of a case against a major pharmaceutical company regarding production violations has ignited increased concern from the Food and Drug Administration. The recent case in question claimed the manufacturer carelessly packaged drugs of varying strengths, different types, broken pills and the presence of microorganisms. is an online platform where investors doing their due-diligence on the drug manufacturers - major industry can have easy and free access to our analyst research and opinions on Bristol-Myers Squibb Co. and Merck & Co. Inc.; all investors need to do is register for a complimentary membership at

The egregious violations occurred almost a decade ago but the case was only settled recently. The settlement has been sufficient to spark further inquiries from the FDA as well as oversight organizations around the world. Global distribution of drugs is becoming an increasingly vital part of Big Pharma's revenues so the recent interest in scrutinizing production is a major cause for concern. Register now at to have free access to our reports on the drug manufacturers - major.

Big Pharma has vowed to a better job of policing itself but the FDA and similar global organizations are adamant about tightening production regulations and increasing the frequency of factory inspections. Inspection failures could lead to settlements in the hundreds of millions like the one seen this month as well as revenue losses and reduced consumer confidence. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

Bristol-Myers Squibb Co. which received a warning from the FDA back in August concerning deficiencies in the implementation of procedures to thwart contamination of sterile drug products at its Puerto Rico-based plant has recently seen its profits for Q3 2010 tumbled by 2 percent to $949 million. This drop in earnings was mainly caused by dreary sales of its drugs, inferior income from its partners and larger discounts to the government as a result of the healthcare reforms. Investors looking for free research on Bristol-Myers Squibb Co. are welcome to sign up at

For Q3 2010 Merck & Co. Inc. saw its earnings dived due to a $950 million Vioxx charge. Investors looking for free research on Merck & Co. Inc. are welcome to sign up at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information